Health Care › Services-Computer Integrated Systems Design
SLP Stock Price Correlated With Simulations Plus Financials
External Links ⌄
Income Statement
Cash Flow
Balance Sheet
SLP Income Statement
Enable JavaScript and reload
Revenue, Net:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
SLP Cash Flow
Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:
SLP Balance Sheet
Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:
COMPANY PROFILE
NOTE 1 – ORGANIZATION AND LINES OF BUSINESS
Organization
Simulations Plus, Inc. (“The Company”)
was incorporated on July 17, 1996. In September 2014, Simulations Plus acquired all of the outstanding equity interests of Cognigen Corporation
(“Cognigen”) and Cognigen became a wholly-owned subsidiary of Simulations Plus, Inc. In June 2017, Simulations Plus acquired
DILIsym Services, Inc. (“DILIsym”) as a wholly-owned subsidiary. In April 2020, Simulations Plus, Inc. acquired Lixoft, a
French société par actions simplifiée (“Lixoft) as a wholly-owned subsidiary pursuant to a stock purchase and
contribution agreement. (Collectively, “Company”, “we”, “us”, “our”).
Effective September 1,
2021, the Company merged both Cognigen Corporation and DILIsym, Services, Inc. with and into Simulations Plus, Inc. through short-form
mergers (the “Mergers”). To effectuate the Mergers, the Company filed Certificates of Ownership with the Secretaries of State
of the states of Delaware (Cognigen’s and DILIsym’s state of incorporation) and California (the Company’s state of incorporation).
Consummation of the Mergers was not subject to approval of the Company’s stockholders and did not impact the rights of the Company’s
stockholders.
Lines of Business
We are a premier developer of drug discovery and
development software for modeling and simulation, and for the prediction of molecular properties utilizing both artificial intelligence
(“AI”) as well as machine learning based technology. We also provide consulting services ranging from early drug discovery
through preclinical and clinical trial data analysis and for submissions to regulatory agencies. Our software and consulting services
are provided to major pharmaceutical, biotechnology, agrochemical, cosmetics and food industry companies, and to regulatory agencies worldwide
for use in the conduct of industry-based research.
Organization
Simulations Plus, Inc. (“The Company”)
was incorporated on July 17, 1996. In September 2014, Simulations Plus acquired all of the outstanding equity interests of Cognigen Corporation
(“Cognigen”) and Cognigen became a wholly-owned subsidiary of Simulations Plus, Inc. In June 2017, Simulations Plus acquired
DILIsym Services, Inc. (“DILIsym”) as a wholly-owned subsidiary. In April 2020, Simulations Plus, Inc. acquired Lixoft, a
French société par actions simplifiée (“Lixoft) as a wholly-owned subsidiary pursuant to a stock purchase and
contribution agreement. (Collectively, “Company”, “we”, “us”, “our”).
Effective September 1,
2021, the Company merged both Cognigen Corporation and DILIsym, Services, Inc. with and into Simulations Plus, Inc. through short-form
mergers (the “Mergers”). To effectuate the Mergers, the Company filed Certificates of Ownership with the Secretaries of State
of the states of Delaware (Cognigen’s and DILIsym’s state of incorporation) and California (the Company’s state of incorporation).
Consummation of the Mergers was not subject to approval of the Company’s stockholders and did not impact the rights of the Company’s
stockholders.
Lines of Business
We are a premier developer of drug discovery and
development software for modeling and simulation, and for the prediction of molecular properties utilizing both artificial intelligence
(“AI”) as well as machine learning based technology. We also provide consulting services ranging from early drug discovery
through preclinical and clinical trial data analysis and for submissions to regulatory agencies. Our software and consulting services
are provided to major pharmaceutical, biotechnology, agrochemical, cosmetics and food industry companies, and to regulatory agencies worldwide
for use in the conduct of industry-based research.
Free historical financial statements for Simulations Plus Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 52 quarters since 2011. Compare with SLP stock chart to see long term trends.
Data imported from Simulations Plus Inc SEC filings. Check original filings before making any investment decision.